undamentalytics Newsletter
Sign in

Biocryst Pharmaceuticals Inc cash flow statement

In fiscal 2025, Biocryst Pharmaceuticals Inc's operations generated $347m of cash; it spent $2.5m on capital projects, leaving free cash flow of $345m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−16−29−32−37−27−39−13−53−41−93−90−135−142−162−95−52347376
Depreciation and amortisation—21100001111112112
Stock-based pay66544101081391815354556658573
Capital spending100000550001212123
Free cash flow−17−29−32−38−27−39−18−59−41−93−90−136−145−163−97−53345373
Free cash flow after stock pay−22−35−37−42−31−49−28−67−54−102−108−150−179−208−153−119260300
Share buybacks000———————————————
Shares issued46—11824107——1345359935000———

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: BBIO vs BCRXBCRX vs KNSABCRX vs IONSBCRX vs LEGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Biocryst Pharmaceuticals Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biocryst Pharmaceuticals Inc.